

Opening Symposium DBMR Mu24-28, March 18th, 2022, 13.30 – 16.15 h



Venue
Auditorium Maurice E. Müller
Operationstrakt Ost (OpO) F
Inselspital, Universitätsspital Bern
3010 Bern

For attendance, please inquire at dirsecretariat@dbmr.unibe.ch.

Program

- 13h30 - 13h40 Welcome – Prof. Mark A. Rubin
Director DBMR, University of Bern
- 13h40 - 13h55 Prof. Hugues Abriel
Vice-Rector for Research, University of Bern
“A new building for Better Science at the University of Bern”

DBMR History

- 13h55 - 14h25 Prof. Willy Hofstetter
“A journey through 30 years of Musculoskeletal Research
and the development of the DBMR –
they’ve both come a long way”
Moderated by: Prof. Abriel

Keynote lectures

- 14h25 - 15h10 Prof. Susan Gasser
“Inching forward: the future of medicine in Switzerland”
Moderated by: Prof. Rubin
- 15h10 - 15h55 Prof. Johann de Bono
“Improving outcome from prostate cancer”
Moderated by: Prof. Kruithof-de Julio
- 15h55 - 16h00 Prof. Anne Angelillo-Scherrer: Announcement winner of the
Johanna Dürmüller-Bol DBMR Research Award 2021 and
of the Benoît Pochon Prize 2021
- 16h00 - 16h10 Johanna Dürmüller-Bol DBMR Research Award 2021
Short presentation by the award recipient
- 16h10 - 16h15 Closing Remarks – Prof. Mark A. Rubin
- 16h15 - 18h00 Apéro at Mu24-28 (4th floor, entrance Mu28)

Short Biographies

Prof. Willy Hofstetter



M.Sc. (Biochemistry), ETHZ, Zurich, Switzerland (1975). Ph.D. (Biochemistry), Children’s Hospital, Inselspital, Bern, Switzerland (1979) (Supervisor: N. Herschkowitz). Postdoctoral fellow, University of Georgia, USA (1983) (Supervisor: D. DerVartanian). Research Associate, Institute of Pathophysiology, University of Bern, Switzerland (1986) (Head: H. Fleisch). Head of the DBMR Research Group for Bone Biology & Orthopedic Research (2007–2021). And more to come (from 2021).

Prof. Susan Gasser



Prof. Gasser completed her PhD in Biochemistry at the University of Basel. She began her independent career at the Swiss Institute for Experimental Cancer Research (ISREC), followed by a professorship at the University of Geneva. From 2004 – 2019, she was the Director of the Friedrich Miescher Institute for Biomedical Research in Basel. She is now professor invit  at University of Lausanne and Director of the ISREC Foundation, where she helps shape the new Agora institute of translational cancer research.

Prof. Johann de Bono



Regius Professor of Cancer Research at The Institute of Cancer Research and honorary consultant in medical oncology at The Royal Marsden Hospital. Professor de Bono leads the Drug Development Unit at the Royal Marsden which comprises >100 staff and conducts >50 Phase I clinical trials at any one time. He also has an interest in prostate cancer. He has been involved in developing more than 200 new agents, several of which are now available to patients, and is currently evaluating more than 30 drugs in early clinical trials. He has published >600 papers including multiple manuscripts in NEJM, Nature, Science, Cell, Lancet and others.
